| Catalog No | Package | Original Price | Price | Inventory | Quantity | Operating |
|---|---|---|---|---|---|---|
| BP5117-5mg | 5mg | $350.00 | Sign in |
|
Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃
5,7-Dihydroxychroman-4-one (CAS No.: 108085-46-7) is a class of natural compounds with significant biological activity and belongs to the chloranone class. In recent years, with the deepening of pharmacological research on natural products, 5,7-dihydroxychlorodan-4-one has gradually become a hotspot in pharmacological research and new drug development due to its unique molecular structure and diverse biological activities. This compound demonstrates significant potential in regulating estrogen-related targets, involving multiple key proteins such as ESR1, ESR2, SHBG, and CYP19A1, demonstrating its application prospects in endocrine regulation and the prevention and treatment of hormone-dependent diseases.
This paper aims to systematically review the chemical structure and physicochemical properties of 5,7-dihydroxychloran-4-one, plant origin, and extraction methods, thoroughly explore its pharmacological activity and mechanism of action, evaluate its druggability parameters and pharmacokinetic characteristics, and finally anticipate its clinical application potential, providing comprehensive reference materials for researchers in related fields.
The chemical structure of 5,7-dihydroxychlorovan-4-one is based on the trypanone framework, with the molecular formula C9H8O4 and a molecular weight of 180.1590. Its structural feature is the presence of two hydroxyl substituents at positions 5 and 7 of the acetanone core, which gives the molecule excellent polarity and hydrogen bond donor capability. The LogP value is 1.2868, indicating moderate lipid solubility, which facilitates cell membrane penetration without being overly hydrophobic, meeting the ideal characteristics of most oral small molecule drugs.
The polar surface area (TPSA) is 66.76 Ų, indicating a certain polarity that facilitates stable binding with protein targets. The water solubility is 1.6921, indicating that this compound has good solubility in aqueous environments, which helps with absorption and distribution in the body. The low permeability of the blood-brain barrier means its penetration ability in the central nervous system is limited, which may reduce central side effects. The hERG channel inhibition test was negative, indicating a low cardiotoxicity risk for this compound. The Ames test result was 0.6, indicating a low genotoxicity risk and a solid safety foundation.
5,7-Dihydroxychloran-4-one is widely found in various traditional medicinal plants, especially those belonging to the legume and rose families. In these plants, this compound mostly exists in free or bound states and often serves as a secondary metabolite, participating in plant defense mechanisms and physiological regulation.
Common plants containing 5,7-dihydroxychloran-4-ketone include certain flavonoid-rich herbaceous and woody plants. The extraction method typically uses organic solvent extraction binder separation technology, with commonly used solvents including methanol, ethanol, and their aqueous solution systems. The extraction process generally includes crushing, soaking, ultrasound-assisted extraction, or reflux extraction of plant materials, followed by purification using silica gel column chromatography, high-performance liquid chromatography (HPLC), and other methods.
In recent years, the application of supercritical CO2 extraction and membrane separation technologies has improved extraction efficiency and purity, reduced the use of organic solvents, and aligned with the concept of green chemistry. Additionally, temperature and pH control during extraction are especially important for the stability of this compound to prevent oxidation of hydroxyl groups and degradation of molecular structure.
Pharmacological activity studies of 5,7-dihydroxychlorotan-4-one mainly focus on its effects on estrogen-regulated diseases. This compound works by regulating multiple estrogen receptors (ESR1, ESR2), as well as associated hormone-binding proteins (SHBG) and metabolic enzymes (CYP19A1), demonstrating potential for anti-estrogen and endocrine balance regulation.
Studies have shown that 5,7-dihydroxychloran-4-ketone exhibits inhibitory effects on tumor cell proliferation and induced apoptosis in hormone-dependent tumor models such as breast cancer and endometrial cancer. Its mechanism partly depends on selective regulation of ERα and ERβ, regulating estrogen signaling pathways within tumor cells and reducing the expression of oncogenes.
The hydroxyl structure of this compound endows it with excellent free radical scavenging ability, demonstrating significant antioxidant activity that can reduce cellular damage related to oxidative stress. Additionally, 5,7-dihydroxychlorovan-4-one exerts anti-inflammatory effects by inhibiting the NF-κB signaling pathway, reducing the release of inflammatory factors such as TNF-α and IL-6.
5,7-Dihydroxytrypan-4-one can regulate the expression of gonadotropin receptors such as FSHR and LHB, affect ovarian function and hormone secretion, and demonstrate its potential in treating polycystic ovary syndrome (PCOS) and other endocrine disorders.
The pharmacological effects of 5,7-dihydroxychlorotan-4-one are mainly realized through interactions with various molecular targets, with particular prominence in estrogen-regulating targets.
This compound can bind to ERα (ESR1) and ERβ (ESR2), exhibiting selective regulatory activity. By modulating receptor conformation, 5,7-dihydroxychloran-4-one affects the receptor's DNA binding ability and transcriptional activity, thereby regulating downstream gene expression. This regulatory action helps balance estrogen signaling and inhibits the abnormal proliferation of estrogen-dependent cells.
5,7-Dihydroxychlorotan-4-one can regulate SHBG expression, affecting the concentration of free estrogen in the blood, thereby modulating hormone bioactivity and tissue distribution.
As a key estrogen synthase, CYP19A1 catalyzes the conversion of androgens into estrogen. 5,7-Dihydroxychlorotan-4-one inhibits CYP19A1 activity, reduces estrogen synthesis, and lowers the risk of hormone-dependent diseases.
This compound also has certain regulatory effects on AR and PGR, participating in the signaling of regulated sex hormones and affecting physiological functions of tissues.
By regulating the expression of FSHR and LHB, 5,7-dihydroxychloran-4-one affects ovarian hormone secretion and reproductive function, suggesting its potential in reproductive endocrine diseases.
The druggability parameters of 5,7-dihydroxychloran-4-one indicate that it has good potential for drug development. The molecular weight of 180.1590 falls within the ideal range of Lipinski's rule, and the LogP is 1.2868, indicating moderate lipid solubility and favorable oral absorption. TPSA is 66.76 Ų, supporting good cell membrane permeability.
The water solubility index of 1.6921 indicates that the compound has good solubility in aqueous solution, which helps with absorption and distribution in the body. The blood-brain barrier has lower permeability, reducing the risk of central nervous system side effects. hERG channel inhibition negative, reducing the risk of cardiotoxicity. Ames trial results showed that it carries a low genotoxicity risk and is relatively safe.
Pharmacokinetic studies show that 5,7-dihydroxychloran-4-one is rapidly absorbed orally and has a moderate plasma half-life. It is mainly metabolized by the liver, with most metabolites being hydroxylated and glucuronic acid conjugates. Its bioavailability is greatly influenced by intestinal enzymes and microbial metabolism. Future formulation improvements can further enhance its in vivo stability and efficacy.
Given the multiple roles of 5,7-dihydroxycotan-4-one in regulating estrogen-related targets, it shows broad clinical application prospects in hormone-dependent diseases such as breast cancer, endometriosis, and polycystic ovary syndrome. Moreover, its anti-inflammatory and antioxidant properties also give it potential as an adjunct therapy for chronic inflammation and metabolic syndrome.
Future research should focus on preclinical safety evaluation, pharmacokinetic optimization, and formulation development of this compound. At the same time, based on the diversity of its molecular targets, structural modification and derivative-like design to enhance selectivity and efficacy will help promote its clinical adaptation.
By combining modern drug screening techniques with systems biology methods, this study will provide in-depth analysis of the in vivo network of action and signaling pathways of 5,7-dihydroxychlorodan-4-one, providing theoretical support and scientific basis for its clinical application.
5,7-Dihydroxychlorovan-4-one, as a natural product with a unique structure and multiple biological activities, is gaining increasing attention for its potential in modulating estrogen-related diseases. Its excellent physicochemical properties and safety foundation lay a solid foundation for drug development. In the future, through systematic pharmacological mechanism research and preclinical evaluation, it is expected to develop into a novel natural drug for treating hormone-dependent diseases.
In summary, 5,7-dihydroxychrome-4-one not not only enriches the research content of natural product pharmacology, but also provides new ideas and strategies for endocrine regulation and the treatment of related diseases, warranting further exploration and development.
